Collaboration Between Bill Gates And Biofarma To Create A COVID-19 Vaccine That Will Be Injected In 2022

JAKARTA - PT Biofarma (Persero) has officially become one of the Potential Drug Manufacturer Coalition for Epidemic Preparedness Innovations (CEPI) for COVID-19. Production of the vaccine will start in the fourth quarter of next year or early 2022 with a production capacity of 100 million doses per year.

For your information, CEPI is a coalition of government, private sector and philanthropy based in Norway, with the aim of overcoming the epidemic by accelerating vaccine development. One of the founders is the Bill & Melinda Gates Foundation.

President Director of Bio Farma, Honesti Basyir, said this decision was a continuation of the results of due diligence, on September 15, 2020, which provided an assessment of aspects of the vaccine production system and its quality, laboratory analytic systems, and information technology systems used by Bio Farma in producing vaccines.

"Currently, the world is trying to find a COVID-19 vaccine with all types of platforms," he said, in Jakarta, Thursday, October 15.

According to Honesti, COVID-19 vaccine developers from around the world, there are those who do not yet have independent mass production facilities, so CEPI will bring them together with vaccine producers who have met certain requirements.

"Biofarma is one of them," he said.

Honesti emphasized that the use of production capacity for CEPI will not affect the routine production activities at Biofarma.

"Of course we have taken into account our routine production activities. After calculating, the use of production capacity for CEPI will not interfere with routine production activities at Biofarma," he said.

In the future, Honesti said, collaboration with CEPI is not limited to the COVID-19 vaccine, but also the development of other vaccines through various latest technologies.

"It is hoped that Biofarma can gain access to various vaccine manufacturing technologies, so that it will strengthen vaccine independence nationally," he said.

The VOI editorial team will continue to monitor all developments made by the world to fight COVID-19 through vaccines. Dear readers, can monitor the development of the COVID-19 vaccine procurement, both domestically and internationally, by touching this link.